



Regenerative Protein Array (RPA)

Is RPA FDA approved?

RPA is in a category of products that the FDA refers to as cell factors. The FDA's position on cell factors is similar to sterile nutraceuticals or drug efficacy study implementation programs for unapproved drugs. The FDA regulates the manufacturing, processing, and distribution, but allows licensed clinicians to make use and care decisions in collaboration with their clients. RPA is produced in an FDA registered facility following Human Cellular Therapy Tissue Product standards.



For more information, visit
www.genesisregenerative.com

Don't Just Relieve... Regenerate.

**New groundbreaking
advancement in anti-aging and
healing is now available to you
and your loved ones.**





Why RPA?

Whether your personal goal is to play more with grandkids, return to the pickleball court, or keep your edge in the boardroom, RPA technology provides the broadest spectrum of healing proteins found in any regenerative product on the market.

What is RPA?

Regenerative Protein Array (RPA) represents a groundbreaking therapy in regenerative medicine. RPA is a sophisticated array of proteins, growth factors, and cytokines derived from placental tissue. This innovative approach is based on the understanding that the therapeutic power of regenerative medicine lies not in the direct transformation of injected cells into target tissues, but rather in their ability to modify the surrounding cellular environment through key biologic messages.

How is RPA Created?

RPA is produced by placing placental tissue in a specialized bioreactor, which nurtures and stimulates the tissue. This process encourages the placenta to produce a rich array of cytokines and growth factors. The resulting product is a concentrated source of bioactive components that are pivotal in tissue regeneration and healing.

Potency and Effectiveness



Application in Medicine

RPA is estimated to be up to 1000 times more potent than conventional treatments like Platelet Rich Plasma (PRP). This potency is attributed to the comprehensive range of regenerative factors present in RPA, which collectively contribute to its superior therapeutic effects.



Mechanism of Action

RPA works by essentially 'reprogramming' the local environment of damaged or diseased tissues. The array of proteins and growth factors in RPA reactivates cellular processes, leading to enhanced transcription and translation activities within the cells. This reactivation aids in restoring the tissue's natural balance and promotes healing and regeneration.



Safety Profile

One of the critical advantages of RPA is its safety. Since the product is devoid of DNA or whole cells, it significantly reduces the risk of adverse reactions, off-target effects, or contraindications associated with other cell-based therapies. This aspect makes RPA a safer alternative for patients and a preferred choice for clinicians.

Conclusion

In summary, RPA is a transformative development in regenerative medicine, offering potent, safe, and versatile treatment options for a range of medical conditions. By harnessing the power of placental derived growth factors and cytokines, RPA opens new avenues in the pursuit of healing and tissue regeneration, making a significant stride forward in medical science.